Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person ERBB2 KD mutants heterodimerize

Class:Id	Reaction:9664567
_displayName	ERBB2 KD mutants heterodimerize
_doRelease	TRUE
_timestamp	2019-11-12 18:14:49
authored	[InstanceEdit:9656339] Orlic-Milacic, Marija, 2019-07-31
compartment	[Compartment:876] plasma membrane [Compartment:70101] cytosol [Compartment:984] extracellular region
created	[InstanceEdit:9664566] Orlic-Milacic, Marija, 2019-10-25
disease	[Disease:1500689] cancer
edited	[InstanceEdit:9665760] Orlic-Milacic, Marija, 2019-11-01
entityFunctionalStatus	[EntityFunctionalStatus:9664569] gain_of_function of ERBB2 KD mutants:ERBIN:HSP90:CDC37 [plasma membrane]
input	[Complex:9646482] ERBB2 KD mutants:ERBIN:HSP90:CDC37 [plasma membrane] [Homo sapiens] [DefinedSet:9667208] Ligand-Activated (EGFR,ERBB3,ERBB4) [plasma membrane] [Homo sapiens]
isChimeric	FALSE
literatureReference	[LiteratureReference:9649397] Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib [LiteratureReference:9646435] Activating HER2 mutations in HER2 gene amplification negative breast cancer [LiteratureReference:9650849] Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations [LiteratureReference:9650832] Anti-tumor effect of neratinib against lung cancer cells harboring HER2 oncogene alterations [LiteratureReference:9652195] Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 [LiteratureReference:9646445] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer [LiteratureReference:9646647] Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface [LiteratureReference:9664473] Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism [LiteratureReference:9647026] An Acquired HER2^T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer [LiteratureReference:9665642] HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
modified	[InstanceEdit:9664756] Orlic-Milacic, Marija, 2019-10-28 [InstanceEdit:9665666] Orlic-Milacic, Marija, 2019-10-31 [InstanceEdit:9666039] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666040] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666041] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9666042] Orlic-Milacic, Marija, 2019-11-01 [InstanceEdit:9667211] Orlic-Milacic, Marija, 2019-11-08 [InstanceEdit:9667512] Orlic-Milacic, Marija, 2019-11-12 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	ERBB2 KD mutants heterodimerize
normalReaction	[Reaction:1963589] ERBB2 forms heterodimers with ligand-activated ERBB receptors: EGFR, ERBB3 and ERBB4 [Homo sapiens]
output	[DefinedSet:9664568] Heterodimers of ERBB2 KD mutants [plasma membrane] [Homo sapiens] [Complex:1221657] HSP90 [cytosol] [Homo sapiens] [Complex:1225828] CDC37 [cytosol] [Homo sapiens] [EntityWithAccessionedSequence:1358718] ERBIN [plasma membrane] [Homo sapiens]
releaseDate	2019-12-10
reviewed	[InstanceEdit:9662685] Kancha, Rama Krishna, 2019-09-16
reviewStatus	[ReviewStatus:9821382] five stars
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9664573] R-HSA-9664567.2
summation	[Summation:9664563] The following ERBB2 KD mutants were directly or indirectly s...
(hasEvent)	[Pathway:9664565] Signaling by ERBB2 KD Mutants [Homo sapiens]
(precedingEvent)	[Reaction:9664588] ERBB2 KD mutants trans-autophosphorylate [Homo sapiens]
(updatedInstance)	[_UpdateTracker:9835704] Update Tracker - [Reaction:9664567] ERBB2 KD mutants heterodimerize - v85:[modifyText]
[Change default viewing format]

No pathways have been reviewed or authored by ERBB2 KD mutants heterodimerize (9664567)